Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Impact of long-term luspatercept treatment on iron parameters in patients with transfusion-dependent and non-transfusion-dependent β-thalassemia: Results from the phase 3b long-term follow-up study

View Full Paper
Ask AI
Bookmark
Share

Authors

PMPatricia Martín-RegueiraGZGeorge Zhang

Discussion

Loading...

Member takes

Overview

Phase 3b study shows long-term luspatercept reduces iron overload in β-thalassemia patients, indicating clinical benefit.

Key Points

  • To evaluate the impact of long-term luspatercept treatment on iron parameters in patients with β-thalassemia.
  • Phase 3b open-label rollover study with patients aged ≥18 years
  • Evaluation of iron parameters from BELIEVE and BEYOND trials
  • Assessment of liver iron concentration, serum ferritin, and myocardial iron
  • Luspatercept treatment led to significant reductions in RBC transfusion burden and iron levels
  • Iron overload indicators like liver iron concentration and serum ferritin improved in TDT patients
  • Stable cardiac T2* levels were maintained during treatment

Cite This Study

Martín-Regueira et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236dad8https://doi.org/10.1182/blood-2025-4695
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Patient‐Reported Outcomes With Luspatercept Through 5 Years of Treatment in Patients With Non‐Transfusion‐Dependent β‐Thalassemia Treated in the <scp>BEYOND</scp> Trial2026
  2. 2Efficacy and safety of luspatercept in non-transfusion-dependent β-thalassemia: long-term results from the BEYOND study2025 · 10 citations
  3. 3Follow‐Up of 3‐Year Luspatercept Treatment in a Transfused ß‐Thalassemia Patient. Bone Marrow: An Undervalued Iron Store2025
  4. 4Luspatercept in β-thalassemia: Meta-analysis of efficacy and safety across transfusion-dependent and non-transfusion-dependent populations2025
  5. 5A clinical study on the Efficacy and safety of luspatercept in Chinese patients with non-transfusion-dependent β-thalassemia2025